Objective: To evaluate the outcome of early treatment in Class I, II, and III malocclusions based on the reduction of weighted Peer Assessment Rating (PAR) scores.
Materials And Methods: Two hundred thirty subjects (female = 105; male = 125) selected from 400 cases were divided into three groups based on their malocclusions (Class I, II, and III). The PAR index was evaluated prior to early treatment (T0), at the end of phase I (T1), and after completion of phase II therapy (T2). The reliability of overall PAR scores was assessed by Bland-Altman plot and intraclass correlation coefficient. The starting age, total weighted PAR scores and their changes after phase I and II treatments, treatment time, and the percentage of correction in the three different malocclusions were assessed by repeated-measures analysis of variance with post hoc analysis. The level of significance was set at P < .05.
Results: More than 30% reduction of the weighted PAR scores and less than 10 points of the remaining weighted PAR scores were observed in all malocclusion groups at T1. The Class III group had the highest percentage of correction during phase I treatment.
Conclusions: Early treatment effectively reduced the complexity of Class I, II, and III malocclusions and accounted for 57%, 64%, and 76% of the total correction, respectively, after phase I treatment, as indicated by an overall reduction in weighted PAR scores. The Class III group responded most favorably to early treatment followed by the Class II group.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288319 | PMC |
http://dx.doi.org/10.2319/091417-618.1 | DOI Listing |
JAMA Netw Open
January 2025
Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.
Importance: Evolving breast cancer treatments have led to improved outcomes but carry a substantial financial burden. The association of treatment costs with the cost-effectiveness of screening mammography is unknown.
Objective: To determine the cost-effectiveness of population-based breast cancer screening in the context of current treatment standards.
J Acquir Immune Defic Syndr
January 2025
Centre for Infectious Disease Epidemiology and Research, School of Public Health, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Background: Data on tuberculosis (TB) incidence and risk factors among children living with HIV (CLHIV) in the universal ART era are limited.
Methods: We analysed routinely-collected data on TB diagnoses for CLHIV age ≤5 years, born 2018-2022, in the Westen Cape, South Africa. We examined factors associated with TB diagnosis, with death and loss to follow-up as competing events.
JAMA Cardiol
January 2025
National Heart and Lung Institute, Imperial College London, United Kingdom.
Importance: Hypertension underpins significant global morbidity and mortality. Early lifestyle intervention and treatment are effective in reducing adverse outcomes. Artificial intelligence-enhanced electrocardiography (AI-ECG) has been shown to identify a broad spectrum of subclinical disease and may be useful for predicting incident hypertension.
View Article and Find Full Text PDFInvest Ophthalmol Vis Sci
January 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.
Purpose: To investigate the 10-year changes in visual function and incidence of visual impairment (VI) in highly myopic eyes.
Methods: This longitudinal study enrolled highly myopic individuals who were followed up for 10 years. All participants underwent detailed ophthalmic examinations at baseline and follow-up visits.
World J Pediatr
January 2025
The First Hospital of Peking University, Beijing, China.
Background: Glucose transporter 1 deficiency syndrome (Glut1DS) was initially reported by De Vivo and colleagues in 1991. This disease arises from mutations in the SLC2A1 and presents with a broad clinical spectrum. It is a treatable neuro-metabolic condition, where prompt diagnosis and initiation of ketogenic dietary therapy can markedly enhance the prognosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!